OPTIC Confirms Teprotumumab Benefit in Thyroid Eye Disease

by Medscape • 2019/04/27 • 0 Comments

Phase 3 findings support practice-changing use of the IGF-1R inhibitor for treating active thyroid-associated ophthalmopathy.
Medscape Medical News